Kombilipid

Kombilipid, the active ingredient in Kombilipid, is a intravenous lipid emulsion presented as an intravenous lipid emulsion for intravenous use. It provides calories and essential fatty acids for patients requiring parenteral nutrition and lipid supplementation. GNH USA supplies Kombilipid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Kombilipid is used in clinical settings to support patients who need intravenous lipid nutrition. - Parenteral nutrition: supplies calories and essential fatty acids when oral intake is not possible. - Essential fatty acid supplementation: prevents deficiency of omega‑3 and omega‑6 fatty acids in long‑term nutrition. - Intravenous lipid supplementation: provides medium‑chain and long‑chain triglycerides for energy and membrane synthesis in critically ill patients.

Kombilipid may be associated with several adverse reactions.

Common Side Effects: - Hypertriglyceridemia: elevated blood triglyceride levels. - Fever or chills during infusion. - Infusion site reactions such as erythema or pain. - Mild electrolyte disturbances, especially phosphate. - Transient increase in liver enzymes. - Lipemia of plasma samples.

Serious or Rare Side Effects: - Fat overload syndrome: severe hyperlipidemia with organ dysfunction. - Anaphylactic or severe allergic reactions, particularly in patients with fish or soy allergy. - Pulmonary embolism from lipid emboli. - Hepatic dysfunction or steatosis with prolonged use. - Coagulopathy due to altered platelet function. - Infection risk if aseptic technique is compromised.

Kombilipid requires careful monitoring and specific handling precautions. - Monitor triglyceride levels: check serum triglycerides regularly during therapy. - Assess liver function: periodic liver enzyme testing is recommended. - Evaluate for allergies: avoid in patients with known hypersensitivity to fish, soy, or olive oil. - Use aseptic technique: ensure sterile preparation and administration to prevent infection. - Caution in fat metabolism disorders: contraindicated in patients with severe hyperlipidaemia or lipid metabolism defects. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Kombilipid can interact with other agents that affect lipid metabolism or increase fat load.

Major Interactions (Avoid): - Concomitant propofol infusion: risk of cumulative lipid overload. - Co‑administration with other intravenous lipid emulsions: may exceed safe fat intake. - High‑dose heparin therapy: can exacerbate hypertriglyceridaemia.

Moderate Interactions (Monitor Closely): - Corticosteroids: may increase serum triglycerides. - Estrogen therapy: can raise triglyceride levels. - High‑dextrose total parenteral nutrition: risk of hyperglycaemia and lipid accumulation.